Misonix Incorporated Announces Presentation At Leading Wound Conference Confirms SonicOne O.R. More Effective At Debridement Of Large Wounds

FARMINGDALE, N.Y., March 17, 2015 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced that SonicOne O.R. was featured in a presentation at the SuperBones/SuperWounds Conference held March 13-15, 2015 in Orlando, Florida.

The SonicOne O.R. is an innovative surgical device that allows surgeons to address the challenges chronic wounds present to them, the patient, and the health-care system. SonicOne O.R. establishes a new standard in surgical wound bed preparation, an essential first step in the wound healing process. Use of the SonicOne O.R. system provides controlled tissue removal, decreased healing times, reduced bleeding and a reduction of biofilm.

Abraham Houng, MD, associate program director for the Division of Burn Surgery at Saint Barnabas Medical Center in Livingston, New Jersey (the 5th largest burn center in the United States) presented, Making Debridement of Large Wounds Easier to an audience of more than 200 wound care clinicians. Dr. Houng commented, “Our expanding experience with the SonicOne O.R. system continues to support a growing body of evidence that debridement with SonicOne O.R. is safer, results in significantly less blood loss, and offers other key advantages over other methods. I was very encouraged by the degree of interest shown by the audience following my presentation. SonicOne O.R. appears to becoming a new standard.”

Conference committee co-chairman, Dr. Lee Rogers, executive medical director of the Amputation Prevention Center in Los Angeles, California, commented, “Dr. Houng’s presentation on his experience with SonicOne O.R. was very well received by our attendees and that was clearly confirmed by the number of clinicians that sought out the Misonix exhibit following the presentation for an opportunity to try the device themselves. As someone who has been using SonicOne O.R. for over a year myself, I would like to add that it is great to see so many of my colleagues and leading institutions discovering the many benefits the SonicOne O.R. offers versus the older waterjet technology that once was used.”

“We have been very encouraged by the growing number of leading clinicians who have elected to incorporate the SonicOne O.R. into patient care protocols at their prominent facilities around the country. Presentations at important meetings, such as the recent SuperBones/SuperWounds Conference, are an important validation of our technology. Additionally, being able to provide attendees an opportunity to trial the system at the meeting is invaluable,” said Michael A. McManus, Jr., president and chief executive officer of Misonix.

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/misonix-announces-presentation-at-leading-wound-conference-confirms-sonicone-or-more-effective-at-debridement-of-large-wounds-300051270.html

SOURCE Misonix, Inc.